ALUMIS INC.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

ALMS$6.40-2.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows


· · Six Months Ended June 30,
(in thousands) · · 2026 · · 2025
Cash flows from operating activities · · · ·
Net loss	$(235,274)	$(39,642)
Adjustments to reconcile net loss to net cash used in operating activities:
Intangible assets impairment loss	41,824	—
Stock-based compensation	26,612	25,630
Net accretion of discounts on marketable securities	(4,035)	(2,152)
Depreciation and amortization	1,745	1,713
Non-cash lease expense	1,091	624
Impairment of long-lived assets	444	—
Gain on bargain purchase in connection with the ACELYRIN Merger	—	(187,907)
Changes in operating assets and liabilities:
Research and development prepaid expenses	(1,479)	7,373
Other prepaid expenses and other assets	64	96
Other assets, non-current	4,392	(1,723)
Accounts payable	2,694	(1,162)
Research and development accrued expenses	791	11,037
Other accrued expenses and current liabilities	(5,933)	6,537
Deferred revenue	2,600	2,611
Operating lease liabilities	(2,322)	(1,349)
Other liabilities, non-current	(39)	168
Deferred tax liability	(1,757)	(8,561)
Net cash used in operating activities	(168,582)	(186,707)
Cash flows from investing activities
Maturities of marketable securities	251,466	144,274
Purchases of marketable securities	(468,058)	(24,535)
Purchases of property and equipment	(401)	(653)
Cash, cash equivalents and restricted cash acquired in connection with the ACELYRIN Merger	—	49,742
Net cash (used in) provided by investing activities	(216,993)	168,828
Cash flows from financing activities
Proceeds from public offering of common stock, net of underwriter discounts, commissions and offering costs	323,797	—
Proceeds from issuance of common stock upon exercise of stock options	34,249	—
Proceeds from issuance of common stock under the 2024 Employee Stock Purchase Plan	1,570	766
Repurchase of common stock issued upon early exercise of stock options	—	(17)
Net cash provided by financing activities	359,616	749
Net decrease in cash, cash equivalents and restricted cash	(25,959)	(17,130)
Cash, cash equivalents and restricted cash at beginning of period	91,053	170,632
Cash, cash equivalents and restricted cash at end of period	$65,094	$153,502
Supplemental disclosures:
Right-of-use assets obtained in exchange for operating lease liabilities	$1,835	$1,776
Stock options exercise proceeds receivable	$724	$—
Vesting of early exercised stock options and unvested restricted shares of common stock	$52	$410
Equity consideration transferred in connection with the ACELYRIN Merger	$—	$238,077
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$63,706	$151,753
Restricted cash	—	367
Restricted cash, non-current	1,388	1,382
Total cash, cash equivalents and restricted cash	$65,094	$153,502

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.